A Phase 2, Double-Blind, Placebo-Controlled, Randomized, International, Multicenter Study of Oral TAC 101 [amsilarotene] as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Amsilarotene (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 03 Jul 2012 Additional trial locations added as reported by European Clinical Trials Database.
- 17 Mar 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.